THE COTTLE GROUP


PUBLICATIONS

Refereed Journal Publications

  1. Rathbone T, Ates I, Cottle RN. Electroporation of CRISPR-Cas9 into freshly isolated primary mouse hepatocytes. Journal of Visualized Experiments, in review.
  2. Rathbone T, Ates I, Fernando L, Addlestone E, Lee C, Richards V, Cottle RN. Electroporation-mediated delivery of Cas9 ribonucleoproteins results in high levels of gene editing in primary hepatocytes. The CRISPR Journal. 2022, online.
  3. Salminen A, Allahyari Z, Gholizadeh S, McCloskey MC, Ajalik R, Cottle RN, Gaborski T, and McGrath JL. In vitro studies of transendothelial migration for biological and drug discovery. Frontiers in Medical Technology. 2020. 2:11.
  4. Ates I, Rathbone T, Stuart C, Bridges PH, Cottle RN. Delivery approaches for therapeutic genome editing and challenges. Genes. 2020. 11:E1113.
  5. Rathbone T, Bryson TE, Bridges PH, Cottle RN. Non-viral mediated delivery of CRISPR-Cas9 and donor templates in hepatocytes to treat inherited metabolic diseases of the liver. Molecular Therapy. 21st Annual Meeting of the American Society of Gene & Cell Therapy Accepted Abstracts. 2018:26, 369-370.
  6. Bryson TE, Anglin CM, Bridges PH, Cottle RN. Nuclease-mediated gene therapies for inherited metabolic diseases of the liver. Yale J Biol Med. 2017. 90:553-66.

    7. Prior To Clemson

  7. Cottle RN, Lee CM, Bao G. Treating hemoglobinopathies using gene-correction approaches: promises and challenges. Hum Genet. 2016. 135:993-100.
  8. Cottle RN, Lee CM, Archer D, Bao G. Controlled delivery of β-globin-targeting TALENs and CRISPR/Cas9 into mammalian cells for genome editing using microinjection. Sci Rep. 2015; 5:16031.

Conference Proceedings

  1. Ates I, Rathbone R, Stuart C., Cottle R. Electroporation-mediated delivery of CRISPR-Cas9 into hepatocytes for treatment of inherited metabolic liver disease,” Proceedings of the AASLD The Liver Meeting. Virtual meeting (November 2021).
  2. Ates I, Rathbone T, Cottle R. Engraftment of hepatocytes gene-edited ex vivo for the treatment of inherited metabolic liver disease,” Proceedings of the 2021 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, Virtual Meeting (August 2021).
  3. Rathbone T, Ates I, Cottle R. Nonviral delivery of CRISPR-Cas9 into primary hepatocytes ex vivo as a therapeutic strategy for inherited metabolic disease,” Proceedings of the 2021 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, Virtual Meeting (August 2021).
  4. O'Neill E, Khodab A, Bisaccio P, OSullivan T, Shropshire K, Cottle R.Disposable Point-of-Care Home Testing Platform for Metabolic Disease. Proceedings of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2021).
  5. Betsill W, Chen A, Cottle R. Genomic Editing and Mutation Repair Using Prime Editors. Proceedings of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2021).
  6. Rathbone T, Ates I, Stuart C, Cottle R. , Comparison of non-viral delivery of cas9 reagents into hepatocytes for therapeutic gene editing. Proceedings of the 2021 SC INBRE Science Symposium, Virtual Meeting (January 2021).
  7. Ates I, Rathbone T, Cottle R. Engraftment of hepatocytes gene edited ex vivo for the treatment of inherited metabolic liver disease. Proceedings of the 2021 SC INBRE Science Symposium, Virtual Meeting (January 2021).
  8. Betsill W, Rathbone T, Lynn S, Cottle R. The effects of buffer composition on the viability and efficiency of electroporation on Huh7 cells. Proceedings of the 2021 SC INBRE Science Symposium, Virtual Meeting (January 2021).
  9. Rathbone T, Ates I, Fernando L, Cottle R. Non-viral delivery of CRISPR-Cas9 for therapeutic gene editing in hepatocytes. Proceedings of the 2019 Meeting on Genome Engineering: Frontiers of CRISPR/Cas9. CSHL, Cold Spring Harbor, NY (October 2019).
  10. Rathbone T, Ates I, Fernando L, Cottle R. Optimization of non-viral methods for delivery of CRISPR-Cas9 and donor templates to treat hereditary tyrosinemia. Proceedings of the 2019 BMES Annual Meeting. BMES, Philadelphia, PA (October 2019).
  11. Nadolski G, Salvadore K, Addlestone E, Fernando L, Cottle RN. Optimization of gene editing tools for precise gene editing. Proceedings of the Focus on Creative Inquiry Poster Forum, Clemson University, Clemson, SC (April 2019).
  12. Cottle R, The promise of cell-based gene therapies using non-viral delivery approaches. Proceeding of the 2nd Annual Summit on Stem Cell Research, Cell & Gene Therapy, Atlanta, GA (November 2018).
  13. Rathbone T, Fernando L, Cottle R. Optimization of non-viral methods for delivery of CRISPR-Cas9 and donor templates to treat familial hypercholesterolemia. Proceedings of the 2018 Annual Meeting. BMES, Atlanta, GA (October 2018).
  14. Bryson T, Rathbone T, Cottle R. Comparison of CRISPR-Cas9 and Cas12a on-target activity in Hepa 1-6 cells. Proceedings of the 2018 Annual Meeting. BMES, Atlanta, GA (October 2018).
  15. Rathbone T, Bryson TE, Bridges PH, Cottle RN. Non-viral mediated delivery of CRISPR-Cas9 and donor templates in hepatocytes to treat inherited metabolic diseases of the liver. Proceedings of the SC INBRE Science Symposium. SC INBRE, Columbia, SC (August 2018). Winner of poster competition for Engineering category.
  16. Cottle R, Novel gene therapy strategy using CRISPR-Cas nucleases and donor template for metabolic liver disease. Proceedings of SC INBRE Science Symposium, Columbia, SC (August 2018).
  17. Rathbone T, Bryson TE, Bridges PH, Cottle RN. Non-viral mediated delivery of CRISPR-Cas9 and donor templates in hepatocytes to treat inherited metabolic diseases of the liver. ASGCT 21st Annual Meeting Abstracts. Molecular Therapy. 2018. 26: 369-370. Chicago, IL (May 2018).
  18. Cottle R, The promise of cell-based gene therapies using non-viral delivery approaches. Proceedings in the International Biomaterials Symposium, Madren Conference Center, Clemson, SC (April 2018).
  19. Bridges PH, Bryson TE, Rathbone T, Cottle RN. CRISPR-Cas9 mediated correction of inherited metabolic disease of the liver. Proceedings of the 3rd Annual Genome Editing & Engineering Conference. San Diego, CA (February 2018).
  20. Rathbone T, Bryson TE, Anglin C, Cottle RN. CRISPR-Cas9 mediated gene modification for correction of familial hypercholesterolemia in mouse hepatocytes. Proceedings of the 2017 Fall Symposium. SC INBRE, Columbia, SC (October 2017).
  21. Bridges PH, Bryson TE, Rathbone T, Cottle RN. Overview of the biomolecular and cellular engineering lab. Proceedings of the 2017 Fall Symposium. SC INBRE, Columbia, SC (October 2017).

    22. Prior to Clemson

  22. Cottle R, Archer D, Bao G. Nuclease mediated genome editing for treating sickle cell disease utilizing non-viral delivery strategies. Proceedings of the 2015 Annual Meeting. BMES, Tampa, FL (October 2015).
  23. Lee C, Lin Y, Preininger M, Cottle R, Cradick TJ, Bao G. Increasing CRISPR specificity for therapeutic applications. Proceedings of the 2014 Annual Meeting. BMES, San Antonio, TX (October 2014).
  24. Cottle R, Archer D, Bao G. Homologous recombination mediated gene repair in K562 cells microinjected with β-globin targeting nucleases using glass microcapillaries. Proceedings from the Pediatric Healthcare Innovation Conference. Emory Children’s Georgia Tech Pediatric Research Alliance, Atlanta, GA (April 2014).
  25. Cottle R, Archer D, Bao G.Genome Editing in CD34+ hematopoietic stem and progenitor cells nucleofected and microinjected with β-globin targeting CRISPR/Cas9. Proceedings from the 2014 Regenerative Medicine Workshop. Parker H. Petit Institute for Bioengineering and Bioscience at the Georgia Institute of Technology, Hilton Head, SC (March 2014).
  26. Cottle R, Sundararaghavan A., Hepler J, Bao G. Protein beacon targeting of inactive heterotrimeric guanine-nucleotide binding protein in live HeLa cells. Proceedings of the 2013 Annual Meeting. BMES, Seattle, WA (September 2013).
  27. Cottle R, David A, Bao D, Bao G. Microinjection-based delivery of beta-globin-targeting TALENs into K562 cells for gene modification. Proceedings of the 2013 Annual Meeting. BMES, Seattle, WA (September 2013).
  28. Cottle R, David A, Bao G. Microinjection-based delivery of β-globin-targeting TALENs into K562 cells for gene modification. Proceedings of the 2013 Pediatric Research Retreat. Emory Children’s Georgia Tech Pediatric Research Alliance, Atlanta, GA (June 2013).
  29. Myers D, Cottle R, Mannino R, Kim H, Bao G, Lam W. Gene correction of rare non-adherent cells using a capture microfluidic and microinjection system. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).
  30. Cottle R, Gang B, Archer D, Wilbur L, Myers D. Quantifying the Effects of Nuclease Delivery on the Functionality of Hematopoietic Stem Cells. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).
  31. Cottle R., Bao G, Hepler J. Protein beacon targeting of endogenous heterotrimeric guanine-nucleotide binding proteins. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).
  32. Sundararaghavan A, Cottle R, Bao G. Quantifying Galpha-I1 subunit protein beacon delivery into live cells permeabilized with streptolysin-o. Proceedings of the 2012 Annual Meeting; BMES, Atlanta, GA (October 2012).

Invited Presentations

  1. Cottle R. “Correcting Inherited Metabolic Liver Disease by ex vivo genome editing using nonviral delivery approaches,” Invited seminar, Biomedical Engineering Seminar, Tufts University, virtual seminar (January 31, 2022)
  2. Cottle R. “Correcting inherited metabolic liver diseases by ex vivo genome editing using nonviral delivery approaches,” Invited seminar, Center for Human Genetics, Clemson University, virtual seminar (September 13, 2021).
  3. Cottle R. “Ex vivo genome editing as a therapeutic approach for genetic diseases”, Invited seminar, Bioengineering Research Seminar, University of Maryland, College Park, MD (February 5, 2021).
  4. Cottle R. “Ex vivo genome editing as a therapeutic approach for genetic diseases”, Invited seminar, Bioengineering Research Seminar, Rochester Institute of Technology, Rochester, NY (March 3, 2020).
  5. Cottle R. “Ex vivo genome editing as a therapeutic approach for inherited metabolic diseases affecting the liver”, Invited seminar, Research Seminar, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA (January 30, 2020)
  6. Cottle R. “Ex vivo genome editing as a therapeutic approach for genetic diseases”, Invited seminar, Research Seminar, Southern Wesleyan University, Central, SC (January 24, 2020).
  7. Cottle R. “Ex vivo genome editing as a therapeutic approach: Engineering the delivery system and critical challenges”, Invited seminar, Regenerative Medicine & Cell Biology, Digestive Disease Research Center Seminar Series, Medical University of South Carolina, Charleston, SC (April 10, 2019).
  8. Cottle R. “Ex vivo genome editing as a therapeutic approach: Engineering the delivery system and critical challenges”, Invited seminar, Seminar Series, Genetics and Biochemistry, Clemson University, Clemson, SC (March 1, 2019).
  9. Cottle R. “The promise of cell-based gene therapies using non-viral delivery approaches”, Invited seminar, Center for Molecular and Translational Medicine, Seminar Series, Georgia State University, Atlanta, GA (November 21, 2018).
  10. Cottle R, “The promise of cell-based gene therapies using non-viral delivery approaches”, Invited conference speech, 2nd Annual Summit on Stem Cell Research, Cell & Gene Therapy, Atlanta, GA (November 9, 2018).
  11. Cottle R, “Towards ex vivo gene editing in hepatocytes for treatment of inherited liver disease”, Invited conference speech, Genetics Symposium, Clemson, SC (September 27, 2018).
  12. Cottle R, “Novel gene therapy strategy using CRISPR-Cas nucleases and donor template for metabolic liver disease”, Invited conference speech, SC INBRE Science Symposium, Columbia, SC (August 10, 2018).
  13. Cottle R, “The promise of cell-based gene therapies using non-viral delivery approaches”, Invited conference speech, International Biomaterials Symposium, Madren Conference Center, Clemson, SC (April 16, 2018).

    14. Prior To Clemson

  14. Cottle R, “Glass microcapillary mediated microinjection of β-globin targeting TALENs into K562 cells”, Graduate and Postdoc Seminar Series, Georgia Institute of Technology, Atlanta, GA (November 13, 2014).
  15. Cottle R, “Microinjection and nucleofection methods of delivering β-globin targeting TALENs into K562 cells”, Nanomedicine Development Center for Nucleoprotein Machines Internal Review Meeting, Atlanta, GA (October 7, 2014).
  16. Cottle R, “Quantifying the effects of nuclease delivery and gene correction on the functionality of hematopoietic stem cells”, Molecular Biophysics Seminar Series, Georgia Institute of Technology, Atlanta, GA (February 6, 2012).

Patents

  1. “Inline Intravenous Fluid Sterilizer”, USA, US 8747764 B1, with SD Reinitz, KE Boucher, and CA Burchman.